Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Breast 1

Conditions

Stomach Neoplasms 2Neoplasm Metastasis 2Breast Neoplasms 2Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Advanced and Metastatic Urothelial Cancer 1

Interventions

Oxaliplatin 53Cisplatin 52Fluorouracil 50Capecitabine 48pembrolizumab 39Leucovorin 31Docetaxel 26Trastuzumab 23Paclitaxel 20Irinotecan 20Ramucirumab 13Bevacizumab 12Cetuximab 9Radiotherapy 8Surgical Procedures, Operative 7S 1 (combination) 7Nivolumab 7Epirubicin 7Carboplatin 6olaparib 5Platinum 5Everolimus 5Sunitinib 4Mitomycin 4trastuzumab deruxtecan 3lenvatinib 3epacadostat 3bemarituzumab 3apatinib 3Saline Solution 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Stomach Neoplasms × futibatinib × Clear all
NCT04189445 2025-10-08

Futibatinib in Patients With Specific FGFR Aberrations

Taiho Oncology, Inc.

Phase 2 Terminated
115 enrolled 19 charts
Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT02052778 2025-03-27

A Study of TAS-120 in Patients With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1/2 Completed
407 enrolled 45 charts 1 FDA
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡